Literature DB >> 20696447

Disodium-fosfomycin pharmacokinetics and bioavailability in post weaning piglets.

A L Soraci1, D S Perez, G Martinez, S Dieguez, M O Tapia, F Amanto, R Harkes, O Romano.   

Abstract

Disodium-fosfomycin pharmacokinetics has been studied in different species after oral, intravenous, intramuscular and subcutaneous administration. At present there are neither documented clinical experiences of the use of fosfomycin in pigs nor any published studies in weaning piglets, although it is a period of high incidence of infectious diseases. The pharmacokinetics and the bioavailability of sodium fosfomycin were studied in post weaning piglets after intravenous and intramuscular administration of 15 mg/kg of body weight. Plasma concentrations were measured by a high-performance liquid ms/ms. After IV administration the area under the fosfomycin concentration:time curve in plasma was AUC(0-12) of 120.00 ± 23.12 μg h/ml and the volume of distribution (Vd) of 273.00 ± 40.70 ml/kg. The elimination was rapid with a plasma clearance of 131.50 ± 30.07 ml/kg/h and a T(1/2) of 1.54 ± 0.40 h. Peak serum concentration (Cmax), Tmax, AUC(0-12) and bioavailability for the IM administration were 43.00 ± 4.10 μg/ml, 0.75 ± 0.00 h, 99.00 ± 0.70 μg h/ml and 85.5 ± 9.90% respectively. Different authors have determined a minimum inhibitory concentration (MIC90) ranging from 0.25 μg/ml for Streptococcus sp. and 0.5 μg/ml for Escherichia coli. Considering the above, and according to the values of plasma concentration vs time profiles observed in this study, effective plasma concentrations of fosfomycin for sensitive bacteria can be obtained following IV and IM administration of 15 mg/kg in piglets.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696447     DOI: 10.1016/j.rvsc.2010.07.011

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  6 in total

1.  Novel integron-mediated fosfomycin resistance gene fosK.

Authors:  Hiromitsu Kitanaka; Jun-ichi Wachino; Wanchun Jin; Satoru Yokoyama; Masa-Aki Sasano; Mitsuhiro Hori; Keiko Yamada; Kouji Kimura; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

Review 2.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 3.  Fosfomycin: Uses and potentialities in veterinary medicine.

Authors:  D S Pérez; M O Tapia; A L Soraci
Journal:  Open Vet J       Date:  2014-03-16

4.  Characterization of Fosfomycin Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Human and Pig in Taiwan.

Authors:  Sung-Pin Tseng; Sheng-Fan Wang; Cheng-Yu Kuo; Jun-Wei Huang; Wei-Chun Hung; Guan-Ming Ke; Po-Liang Lu
Journal:  PLoS One       Date:  2015-08-17       Impact factor: 3.240

5.  Penetration of fosfomycin into IPEC-J2 cells in the presence or absence of deoxynivalenol.

Authors:  Guadalupe Martínez; Denisa S Pérez; Alejandro L Soraci; María O Tapia
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

6.  Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.

Authors:  Ilya Nikolaevich Zykov; Ørjan Samuelsen; Lotte Jakobsen; Lars Småbrekke; Dan I Andersson; Arnfinn Sundsfjord; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.